TriSalus Life Sciences

We are grateful for our partnership with Colorado BioScience Institute

We are pleased to have acted as Sole Dealer Manager to TriSalus Life Sciences, Inc. on its Public Warrant Exchange of 7.0 Million Warrants.

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

Thank you Colorado BioScience Institute. We are proud to be part of the externship program.

Our CEO, Mary Szela, recently spoke to Simon King, FirstWord's editor-in-chief of pharmaceutical news analysis about our company's novel approach to drug delivery for the novel treatment of high pressure tumors. Below you can find the link to read the entire article.

Dr. Steven Katz, TriSalus’ Chief Medical Officer, will be hosting a workshop this Thursday, June 20th, during the 5th Annual STING & TLR Targeted Therapies Summit, discussing Advancing Translational Models for Improving Predictive Biologic Effects {or Immune Responses} of Innate Immune System-Targeted Therapies.   Dr. Katz will also be presenting this Wednesday, June 19th, at 1:45pm PT on TME Modelling & Dose Optimization for Solid Tumor Immunotherapy Development – the TriSalus Translational & Clinical Experience, showcasing data from our PERIO trials.

We love being part of this program with Colorado BioScience Institute. This year we are excited to host Nicole King. Welcome Nicole! #Cancer #MedDevice #HCC #ICC #PancreaticCancer Zaragoza Briseno Jr.

Check out our careers page. We are hiring! R&D Engineer II Sr. R&D Engineer/Project Lead Sales & Marketing Support Specialist Field Clinical Specialist (NE Region: NYC, Metro Manhattan, Brooklyn, Queens) Field Clinical Specialist (SE Region: Atlanta) Field Clinical Specialist (SE Region: South Carolina) Quality Control Inspector

Would you like to learn more about TriSalus? You can hear more about our company from our Chairman of the Board, Mats Wahlstrom and Board Director, Kerry Hicks here:

On Saturday, we presented Phase 1b clinical data from our PERIO-02 study, investigating nelitolimod in Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma as a poster presentation at the American Society of Clinical Oncology 2024 Annual Meeting. #ASCO24. For full details on the presentation and data, read today’s press release: https://lnkd.in/gvPePdea #ASCO24 #HCC #ICC